Phase I/II study of streptozocin monotherapy in Japanese patients with unresectable or metastatic gastroenteropancreatic neuroendocrine tumors

被引:5
作者
Komoto, Izumi [1 ]
Kokudo, Norihiro [2 ,7 ]
Aoki, Taku [2 ,8 ]
Morizane, Chigusa [3 ]
Ito, Tetsuhide [4 ,9 ]
Hashimoto, Takuya [5 ]
Kimura, Wataru [6 ]
Inoue, Naoya [1 ]
Hasegawa, Kiyoshi [2 ]
Kondo, Shunsuke [3 ]
Ueno, Hideki [3 ]
Igarashi, Hisato [4 ,10 ]
Oono, Takamasa [4 ,11 ]
Makuuchi, Masatoshi [5 ]
Takamoto, Takeshi [5 ]
Hirai, Ichiro [6 ]
Takeshita, Akiko [6 ,12 ]
Imamura, Masayuki [1 ,13 ]
机构
[1] Kansai Elect Power Hosp, Dept Surg, Osaka, Japan
[2] Univ Tokyo Hosp, Dept Surg, Hepatobiliary Pancreat Surg Div, Tokyo, Japan
[3] Natl Canc Ctr, Dept Hepatobiliary & Pancreat Oncol, Tokyo, Japan
[4] Kyushu Univ, Grad Sch Med Sci, Dept Med & Bioregulatory Sci, Fukuoka, Japan
[5] Japanese Red Cross Med Ctr, Div Hepatobiliary Pancreat Surg, Tokyo, Japan
[6] Yamagata Univ, Dept Gastroenterol Breast Thyroid & Gen Surg, Fac Med, Yamagata, Japan
[7] Natl Ctr Global Hlth & Med, Tokyo, Japan
[8] Dokkyo Med Univ Hosp, Mibu, Tochigi, Japan
[9] Int Univ Hlth & Welf, Fukuoka Sanno Hosp, Fukuoka, Japan
[10] Igarashi Med Clin, Yamaguchi, Japan
[11] Natl Hosp Org Kyushu Canc Ctr, Fukuoka, Japan
[12] Okitama Publ Gen Hosp, Yamagata, Japan
[13] Kansai Elect Power Hosp, Neuroendocrine Tumor Ctr, Osaka, Japan
关键词
neuroendocrine tumor; streptozocin; disease control; tumor shrinkage; CHEMOTHERAPY; DOXORUBICIN; 5-FLUOROURACIL; FLUOROURACIL; EPIDEMIOLOGY; EVEROLIMUS;
D O I
10.1093/jjco/hyac048
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background This phase I/II study was conducted to evaluate the efficacy, safety and pharmacokinetics of streptozocin (STZ) in Japanese patients with unresectable or metastatic gastroenteropancreatic neuroendocrine tumors. Methods Twenty-two patients received up to 4 cycles of intravenous STZ at either 500 mg/m(2) once daily for 5 consecutive days every 6 weeks (daily regimen) or at 1000-1500 mg/m(2) once weekly for 6 weeks (weekly regimen). Tumor response was evaluated using the modified RECIST criteria ver. 1.1, and adverse events were assessed by grade according to the National Cancer Institute CTCAE (ver. 4.0). Results Fourteen (63.6%) patients completed the study protocol. No patients had complete response; partial response in 2 (9.1%), stable disease in 17 (77.3%), non-complete response/non-progressive disease in 2 (9.1%) and only 1 (4.5%) had non-evaluable disease. Excluding the latter, the response rate in the daily and weekly regimens was 6.7% (1/15) and 16.7% (1/6), respectively, with an overall response rate of 9.5% (2/21). However, the best overall response in each patient showed that the disease control rate was 100%. Adverse events occurred in all 22 patients, including 17 grade 3 adverse events in 11 patients; however, no grade 4 or 5 adverse events were reported. Prophylactic hydration and antiemetic treatment reduced the severity and incidence of nephrotoxicity, nausea and vomiting. Plasma STZ concentrations decreased rapidly after termination of infusion, with a half-life of 32-40 min. Neither repeated administration nor dose increases affected pharmacokinetic parameters. Conclusions STZ may be a useful option for Japanese patients with unresectable or metastatic gastroenteropancreatic neuroendocrine tumors. In a phase I/II study, streptozocin in a daily or weekly regimen was effective and well-tolerated in 22 Japanese patients with unresectable or metastatic gastroenteropancreatic neuroendocrine tumors.
引用
收藏
页码:708 / 716
页数:9
相关论文
共 26 条
[1]  
ADOLPHE AB, 1975, CANCER CHEMOTH REP 1, V59, P547
[2]   Streptozocin chemotherapy for advanced/metastatic well-differentiated neuroendocrine tumors: an analysis of a multi-center survey in Japan [J].
Aoki, Taku ;
Kokudo, Norihiro ;
Komoto, Izumi ;
Takaori, Kyoichi ;
Kimura, Wataru ;
Sano, Keiji ;
Takamoto, Takeshi ;
Hashimoto, Takuya ;
Okusaka, Takuji ;
Morizane, Chigusa ;
Ito, Tetsuhide ;
Imamura, Masayuki .
JOURNAL OF GASTROENTEROLOGY, 2015, 50 (07) :769-775
[3]  
Basch Ethan, 2012, Am Soc Clin Oncol Educ Book, P532, DOI 10.14694/EdBook_AM.2012.32.532
[4]  
Cheng PNM, 1999, CANCER, V86, P944, DOI 10.1002/(SICI)1097-0142(19990915)86:6<944::AID-CNCR8>3.3.CO
[5]  
2-G
[6]   Phase III trial of chemotherapy using 5-fluorouracil and streptozotocin compared with interferon α for advanced carcinoid tumors: FNCLCC-FFCD 9710 [J].
Dahan, Laetitia ;
Bonnetain, Frank ;
Rougier, Philippe ;
Raoul, Jean-Luc ;
Gamelin, Eric ;
Etienne, Pierre-Luc ;
Cadiot, Guillaume ;
Mitry, Emmanuel ;
Smith, Denis ;
Cvitkovic, Frederique ;
Coudert, Bruno ;
Ricard, Floriane ;
Bedenne, Laurent ;
Seitz, Jean-Francois .
ENDOCRINE-RELATED CANCER, 2009, 16 (04) :1351-1361
[7]   New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [J].
Eisenhauer, E. A. ;
Therasse, P. ;
Bogaerts, J. ;
Schwartz, L. H. ;
Sargent, D. ;
Ford, R. ;
Dancey, J. ;
Arbuck, S. ;
Gwyther, S. ;
Mooney, M. ;
Rubinstein, L. ;
Shankar, L. ;
Dodd, L. ;
Kaplan, R. ;
Lacombe, D. ;
Verweij, J. .
EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :228-247
[8]  
ERIKSSON B, 1990, CANCER-AM CANCER SOC, V65, P1883, DOI 10.1002/1097-0142(19900501)65:9<1883::AID-CNCR2820650902>3.0.CO
[9]  
2-3
[10]   Optimal strategy of systemic treatment for unresectable pancreatic neuroendocrine tumors based upon opinion of Japanese experts [J].
Ikeda, Masafumi ;
Morizane, Chigusa ;
Hijioka, Susumu ;
Matsumoto, Shigemi ;
Konishi, Tsuyoshi ;
Komoto, Izumi ;
Aoki, Taku ;
Ito, Tetsuhide ;
Furuse, Junji ;
Sasano, Hironobu ;
Doi, Ryuichiro .
PANCREATOLOGY, 2020, 20 (05) :944-950